As a novel EGFR TKI that targets several EGFR mutations and HER2 amplification, it is worth conducting further research to understand PCC0208027 activity, in order to provide more feasible EGFR TKI options for NSCLC treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.